U.S OFFICE: , 3 BETHESDA METRO CENTRE, BETHESDA, MARYLAND, 20814(877) 424-2429INFO@CANNABICS.COM
http://www.cannabics.com/ http://www.cannabics.com/investors/ https://twitter.com/cannabics1 http://www.cannabics.com/news/
Cannabics Pharmaceuticals is dedicated to the development of Personalized Anti-Cancer treatments.
Our main focus is the development of novel therapies and biotechnological tools aimed to providing relief from diverse ailments and treat human malignancies. These advanced tools include novel delivery systems, personalized medicine diagnostics and therapies based on Cannabinoid compounds.
Cannabics scientific research is devoted to create tailored therapies for cancer patients, utilizing advanced High-throughput screening (HTS) diagnostics and personalized bioinformatics tools.
The Company’s principal product is Cannabics SR' a long acting oil capsule that provides a safe, effective and reliable administration of cannabis. Composed solely from food grade materials, Cannabics SR' 5-10mg delivers a steady level of beneficial effects for 4–8 hours.
Cannabics Pharmaceuticals Inc. is traded in the US OTC stock exchange, under the trade symbol: CNBX
"Cannabics SR', is a long acting oil capsule that provides a safe, effective and reliable administration of cannabis."
Cannabics SR' Capsules, Technology Description - Route of administration
There is a growing number of patients, worldwide, who could benefit from the therapeutic properties of cannabinoids. The unmet need of these patients is a safe, standardized and easy to administer cannabinoid-based therapy. Cannabinoid administration is mainly through smoking, vaporizing, sublingual and oral. While clinical studies show contradictory data regarding a correlation between smoking cannabis and respiratory diseases, most physicians agree that smoking medical cannabis, while having its benefits, is not a healthy nor standardized therapy.
The pharmacokinetics of THC varies as a function of its route of administration. Pulmonary assimilation of inhaled THC causes a maximum plasma concentration within minutes; psychotropic effects start within seconds to a few minutes, reach a maximum after 15–30 minutes, and taper off within 2–3 hours. Following oral ingestion, psychotropic effects set in with a delay of 30–90 minutes, reach their maximum after 2–3 hours and last for about 4–12 hours, depending on dose and specific effect. Another common route of administration is sublingually. Pure cannabinoids are extracted from the raw plant, dissolved in different oils and administered with a dropper. The beneficial effect of sublingual oil administration is 2-4 hours with a fast onset due to quick absorption through the oral cavity.
The most common oral administration of cannabinoids is through eating edibles, mainly, cookies, chocolate bars and lozenges. Since absorption is attenuated when cannabinoids are ingested orally, Edibles usually contain high dosages of cannabinoids (50-300mg). The high dosage may cause undesirable side effects, mainly, dizziness, anxiety and dissociation. These side effects cause many patients to withdraw from the therapeutic process. The oral administration route has the longest beneficial effect (4-8 hours) and lacks the undesirable effects of smoking.
Technology currently envisions the licensing of three different formulations: capsules with a 10:1 CBD to THC ratio, a 10:1 THC to CBD ratio and a balanced formulation with 1:1 THC:CBD.
Cannabics Pharmaceuticals Inc. does not manufacture, distribute, dispense or possess any controlled substances, including cannabis or cannabis based preparations.
CNBX Security Details
https://finance.yahoo.com/q?s=cnbx&fr=uh3_finance_web&uhb=uhb2 Cannabics Pharmaceuticals Inc. is a US based company founded in 2012 by Israeli researchers from the fields of molecular biology and cancer.
| ||Market Value1 ||$37,994,466 ||a/o Oct 28, 2016 |
| ||Authorized Shares ||900,000,000 ||a/o Jul 09, 2015 |
| ||Outstanding Shares ||107,026,665 ||a/o Jun 30, 2016 |
| ||-Restricted ||Not Available |
| ||-Unrestricted ||Not Available |
| ||Held at DTC ||Not Available |
| ||Float ||18,737,071 ||a/o Jun 30, 2016 |
| ||Par Value ||0.0001 |
The Company's scientific focus is on harnessing the proven therapeutic properties of natural Cannabinoids and to create tailored therapies for cancer patients, utilizing advanced HTS technology and personalized bioinformatics tools.
The Company's R&D is based in Israel, where it is fully licensed by The Ministry of Health and involves both scientific and academic research as well as current ongoing medical clinical studies which are registered with the US NIH.
The Company new clinical study examine the effectiveness of Cannabics SR capsules as treatment to improve cancer related CACS (Cachexia and Anorexia) in advanced cancer Patients. While this study is taking place in Israel, it is fully registered with the US NIH under "Cannabics Capsules as Treatment to Improve Cancer Related CACS in Advanced Cancer Patients", identifier NCT02359123 and can be found at: https://clinicaltrials.gov/ct2/show/NCT02359123 What is A Cannabinoid? You’ve heard by now that marijuana is a powerful medicinal herb. But, just how powerful is it? The list of medical benefits for these top 10 cannabinoids seems endless.